Published in Medical Letter on the CDC and FDA, March 21st, 2004
The system is a dual action technology (thermodilatation), employing heat and urethral dilatation to provide significant symptomatic improvement in 2 weeks. This device is used in an in-office procedure that minimizes patient discomfort and the need for post-treatment catheterization.
In a randomized 1-year clinical trial, conducted at 14 centers across the United States,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA